eseo-d-3-q-1

Name(Required)

Conference ID(Required)

1- Which of the following patients’ profiles, vildagliptin is contraindicated to be added on the treatment regimen?(Required)

A. History of myocardial infarction

B. Moderate renal impairment

C. Patient is on oral GLP-1

D. Patient is on basal insulin

2- Which glucose-lowering therapy is recommended to be added to such a patient?(Required)

A. Shift to long-acting Basal insulin

B. Dipeptidyl peptidase 4 inhibitor

C. SGLT2

D. Sulphonylurea

3- What is the recommended dose of vildagliptin to be given to this patient?(Required)

A. 50 mg BID

B. 25 mg BID

C. 50 MG OD

D. 100 OD

4- Which of the following classes of Glucose lowering agents is better to be avoided in PTD?(Required)

A. SGLT-2 inhibitors

B. GLP-1 receptor agonists

C. TZDs

D. DPP4 inhibitors

Scroll to Top